09/22/2017

The FDA granted accelerated approval to OPDIVO (nivolumab) for the treatment of hepatocellular carcinoma (HCC)

The FDA has approved Opdivo (nivolumab) injection for intravenous use for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Approval for this indication has been granted under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

For more information, click here.